Genmab Bundle
Who Owns Genmab?
Understanding a company's ownership is key to grasping its direction and influence. Genmab A/S, a Danish biotech firm founded in 1999, has evolved significantly since its inception.
Genmab's journey from a startup to a major player in antibody therapeutics, including its success with products like DARZALEX, highlights its strategic growth and market impact.
Genmab operates as a publicly traded entity, with its shares available on the Copenhagen Stock Exchange (Nasdaq Copenhagen: GMAB) and its American Depositary Receipts (ADRs) on the NASDAQ in the US (NASDAQ: GMAB). In 2023, the company achieved revenues of DKK 16.474 billion, supported by a workforce of 2,204 employees. This scale reflects its established presence in the biotechnology sector, driven by the development and commercialization of innovative antibody treatments. The company's strategic direction and governance are influenced by its diverse shareholder base, which includes significant institutional investors and the broader public market. A deeper look into its Genmab Porter's Five Forces Analysis can further illuminate its competitive positioning.
Who Founded Genmab?
Genmab A/S was established in February 1999, with Florian Schönharting, then managing director of BankInvest Biomedical venture fund, and Lisa N. Drakeman as its founders. Drakeman, a former vice president at Medarex, took on the role of CEO and joined the board upon the company's incorporation. Jan Van de Winkel was also a key co-founder, serving as Chief Scientific Officer before becoming President and CEO in 2010.
The initial vision for Genmab was to create a leading European biotechnology company focused on developing innovative antibody therapies. This strategy, supported by early investors, aimed to capitalize on the growing understanding of monoclonal antibodies in treating complex diseases. The company's early history is a testament to the power of combining scientific expertise with a clear commercial objective, as detailed in the Marketing Strategy of Genmab.
Key Founders and Roles
The foundational team comprised individuals with significant experience in biotechnology and venture capital. Their combined expertise was instrumental in shaping Genmab's early direction and securing initial funding.
- Florian Schönharting: Initiated the company and provided early venture capital.
- Lisa N. Drakeman: Served as the first CEO and board member, bringing experience from Medarex.
- Jan Van de Winkel: Co-founded the company and led its scientific direction as CSO.
Genmab SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Genmab’s Ownership Changed Over Time?
Genmab's journey from its inception to its current standing as a publicly traded entity has been marked by significant milestones that shaped its ownership structure. The company's initial public offering in October 2000 on the Copenhagen Stock Exchange, which raised a record DKK 1.56 billion for a European biotech firm, was a pivotal moment. This was followed by a second public offering in January 2006, securing an additional DKK 800 million.
| Event | Date | Impact on Ownership |
| Initial Public Offering (IPO) | October 2000 | Transitioned from private to public ownership, raising DKK 1.56 billion. |
| Second Public Offering | January 2006 | Further capital infusion, raising DKK 800 million, broadening the shareholder base. |
| US IPO (ADRs on NASDAQ) | July 2019 | Expanded access to US investors, raising $506 million. |
As of July 21, 2025, Genmab's stock was trading at $21.69 per share, with a market capitalization of $13.40 billion. The Genmab ownership structure is a blend of various investor types, including institutional, retail, and individual shareholders. Institutional investors collectively hold approximately 1.65% of the company's stock, while public companies and individual investors account for 98.35%. Insiders, such as company executives and board members, hold about 0.86% of the shares. This diverse ownership profile indicates a broad base of support for Genmab company, with significant influence from institutional players.
Genmab Major Shareholders
Understanding who owns Genmab is crucial for assessing its stability and future direction. Key institutional investors play a significant role in Genmab's stock ownership.
- Alliancebernstein L.P. held 14,725,158 shares as of March 31, 2025.
- Orbis Allan Gray Ltd held 5,710,741 shares as of March 31, 2025.
- Citadel Advisors Llc held 4,426,654 shares as of March 31, 2025.
- BlackRock, Inc. held 3,517,852 shares as of March 31, 2025.
- Baillie Gifford & Co. held 4.99% of the share capital and voting rights as of October 3, 2024.
- The top 25 Genmab company shareholders collectively own 39% of the company.
The substantial capital raised through its public offerings and ADR listing has been instrumental in fueling Genmab's extensive research and development initiatives. This financial backing has enabled the company to advance its pipeline and successfully commercialize key products, such as DARZALEX. The evolution of Genmab's ownership structure, particularly the increasing weight of institutional investors, highlights the company's growth and its appeal in the global financial markets. For those interested in the company's trajectory, exploring its Brief History of Genmab provides valuable context on its development and strategic decisions that have influenced its shareholder base.
Genmab PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Genmab’s Board?
Genmab's Board of Directors is responsible for the company's strategic direction and governance, operating under a 'comply-or-explain' approach to corporate governance recommendations. The board's composition and oversight are detailed in the company's Statutory Corporate Governance Report for 2024.
| Board Role | Name | Key Affiliation/Role |
|---|---|---|
| Board Chair | Deirdre P. Connelly | Board Chair |
| President & CEO | Jan Van de Winkel | Co-founder, Professor of Immunotherapy |
| Board Member | (Information not fully available for July 2025) | (Nominating and Corporate Governance Committee identifies candidates) |
The Nominating and Corporate Governance Committee plays a vital role in identifying and recommending candidates for the Board of Directors, ensuring a robust and experienced leadership team. Jan Van de Winkel, a co-founder and the current President and CEO since 2010, also holds a professorship in immunotherapy at Utrecht University. As of May 9, 2025, Jan G.J. van de Winkel held 1.0% of the company's shares, underscoring a significant personal stake in the company's success. Genmab's commitment to transparency is evident through various communication channels, including company announcements and investor meetings, aiming to build trust with its stakeholders. The company generally adheres to a one-share-one-vote principle, a standard practice for publicly traded entities, without specific indications of preferential voting rights for any particular shareholder groups.
Understanding Genmab's Governance
Genmab's governance framework is designed to ensure accountability and ethical operations. The board's structure and the company's adherence to corporate governance recommendations are key aspects of its investor relations.
- Adherence to Recommendations for Corporate Governance.
- Focus on ethical and compliant conduct.
- Transparent communication with shareholders.
- The Nominating and Corporate Governance Committee's role in board selection.
- The Competitors Landscape of Genmab provides context for its market position.
Genmab Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Genmab’s Ownership Landscape?
Genmab's ownership profile is dynamic, influenced by its robust financial performance and strategic expansion over the past few years. Recent developments, including significant acquisitions and strong revenue growth, are shaping its shareholder landscape and attracting continued investment interest.
| Financial Metric | 2024 (Full Year) | Q1 2025 |
| Revenue | DKK 21,526 million | $715 million (up 19% YoY) |
| Operating Profit | N/A | $188 million (up 62% YoY) |
| Expected 2025 Revenue | N/A | $3.3 - $3.7 billion |
Genmab's recent strategic moves, such as the acquisition of ProfoundBio Inc. in May 2024, have significantly expanded its pipeline and technological capabilities. This acquisition, which brought in promising candidates like rinatabart sesutecan and novel ADC technology platforms, underscores the company's commitment to innovation and growth. Furthermore, the initiation of a share buyback program in March 2025, targeting up to 2.2 million shares, signals strong confidence in the company's future prospects and a dedication to enhancing shareholder value. These developments are occurring within a broader industry trend of increasing institutional ownership in the biotechnology sector. While retail investors currently hold a substantial portion of Genmab's stock at 98.35%, institutional investors, despite holding approximately 1.65%, wield considerable influence due to the volume of shares they manage. BlackRock, Inc., for instance, is a notable large shareholder with 6.5% ownership as of May 9, 2025. The company's consistent financial achievements and pipeline advancements are expected to further attract institutional capital, potentially leading to shifts in the overall Genmab ownership structure. Strategic collaborations with major entities like Johnson & Johnson and Novartis also reinforce Genmab's market position and growth trajectory, aligning with its ambitious 2030 vision to develop 'knock-your-socks-off (KYSO) antibody medicines' for serious diseases.
Share Buyback Initiative
In March 2025, Genmab announced a planned share buyback of up to 2.2 million shares. This action reflects management's confidence in the company's valuation and future growth potential.
ProfoundBio Acquisition
The acquisition of ProfoundBio Inc. in May 2024 significantly bolstered Genmab's pipeline. It provided access to promising drug candidates and advanced antibody-drug conjugate technology platforms.
Institutional Investor Influence
While retail investors hold the majority of shares, institutional investors like BlackRock, Inc. (6.5% ownership as of May 9, 2025) significantly influence Genmab's stock through their substantial holdings.
Strategic Collaborations and Vision
Partnerships with companies like Johnson & Johnson and Novartis are key to Genmab's growth. The company's long-term vision focuses on transforming patient lives through innovative antibody medicines, as detailed in the Revenue Streams & Business Model of Genmab article.
Genmab Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Genmab Company?
- What is Competitive Landscape of Genmab Company?
- What is Growth Strategy and Future Prospects of Genmab Company?
- How Does Genmab Company Work?
- What is Sales and Marketing Strategy of Genmab Company?
- What are Mission Vision & Core Values of Genmab Company?
- What is Customer Demographics and Target Market of Genmab Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.